Unicycive Therapeutics (UNCY) Cash from Operations (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Cash from Operations came in at 6241000.0 in Q1 2026, up 29.9% YoY from 4804463.73 in Q1 2025, and up 22.3% on a QoQ basis from 8032000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Cash from Operations (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Cash from Operations data on file, last reported at 6241000.0 in Q1 2026.
- Quarterly Cash from Operations rose 29.9% year-over-year to 6241000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28655000.0 (up 7.63% YoY) and the FY2025 annual result came in at 31317000.0, down 9.6% from the prior year.
- Cash from Operations improved to 6241000.0 in Q1 2026, from 8032000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2957000.0 in Q1 2022 to a low of 9252000.0 in Q3 2024.
- A 5-year average of 5886294.12 and a median of 6084000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations slumped 1304.15% — and 2025, when it jumped 35.56%.
- Tracing UNCY's Cash from Operations over 5 years: stood at 6084000.0 in 2022, then grew by 27.04% to 4439000.0 in 2023, then tumbled by 47.51% to 6548000.0 in 2024, then decreased by 22.66% to 8032000.0 in 2025, then rose by 22.3% to 6241000.0 in 2026.
- The last three Cash from Operations figures came in at 6241000.0 (Q1 2026), 8032000.0 (Q4 2025), and 5962000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | -7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.60 Mn |
| Jun 30, 2026 | -7.60 Mn |
| Mar 31, 2026 | -6.24 Mn |
| Mar 31, 2026 | -6.24 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Dec 31, 2025 | -8.03 Mn |
| Sep 30, 2025 | -5.96 Mn |
| Sep 30, 2025 | -5.96 Mn |
| Jun 30, 2025 | -8.42 Mn |
| Jun 30, 2025 | -8.42 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | -6.55 Mn |
| Dec 31, 2024 | -6.55 Mn |
| Sep 30, 2024 | -9.25 Mn |
| Sep 30, 2024 | -9.25 Mn |
| Jun 30, 2024 | -6.32 Mn |
| Jun 30, 2024 | -6.32 Mn |
| Mar 31, 2024 | -6.46 Mn |
| Mar 31, 2024 | -6.46 Mn |